Where we are: The FTSE 100 is trading marginally firmer around the 8,240 level this Friday lunchtime, recovering some poise but still on track for a 0.5% weekly loss. The index has carved out an intraday range of 8,205 to 8,260, anchored by defensive bid sectors while high-beta resource names drag. Today’s constructive price action has clawed back yesterday’s late-session weakness, but the index remains capped below its key 50-day moving average at 8,280. A clean close above 8,250 is required before the New York long-weekend to prevent a deeper technical slide toward psychological support at 8,100.
What’s driving it: UK equities are digesting a robust domestic macro picture after UK retail sales rebounded by 1.2% in May, comfortably beating the 0.5% forecast and highlighting resilient consumer demand despite the Bank of England holding rates at 3.75% yesterday. This consumer resilience, coupled with sticky Core CPI ticking up to 2.6%, keeps domestic gilt yields well-supported and limits the scope for near-term BoE monetary easing. Further complicating the domestic landscape, the PRA’s newly published Basel 3.1 market risk internal model consultation has triggered a sharp sector rotation, dragging major lenders lower. This financial sector headwind is being partially offset by a strong defensive bid in pharma giants and a recovery in oil majors as WTI crude stabilized near $84.65.
- The 1.2% rebound in UK retail sales, combined with May public sector net borrowing hitting £23.3 billion, underscores a sticky fiscal and demand backdrop that reinforces the BoE’s hawkish hold at 3.75%.
- The PRA’s Basel 3.1 market risk consultation has immediately hit domestic banks, with Lloyds dropping 1.8% and Barclays shedding 0.9% as traders price in stricter capital model adjustments.
- Defensive healthcare names are acting as the primary index stabilizer, with AstraZeneca climbing 1.6% and GSK up 0.9%, decoupling from the broader global equity soft patch signaled by yesterday’s 12.3% spike in the VIX to 18.44.
NY session focus: As we head into the New York open, macro focus shifts to the US data slate at 08:30 ET, where any hawkish surprises will push US 10-year yields back above 4.50% and put further pressure on global interest-rate-sensitive sectors. For the afternoon session, we are watching the 8,200 level closely on the UK100; a breakdown here opens the path to 8,150, while a break above 8,260 targets 8,300. The trade that is working is long defensive pharma against short domestic banks, while the long-gilt proxy trade remains highly vulnerable to global real-yield extensions. The pain trade is a sharp short-covering squeeze in UK banks if New York accounts view the PRA’s Basel 3.1 adjustments as already fully discounted.